Melinta Therapeutics (Melinta Therapeutics) ROE % Adjusted to Book Value : 0.00% (As of Sep. 2019)

View and export this data going back to 2012. Start your Free Trial

What is Melinta Therapeutics ROE % Adjusted to Book Value?

Melinta Therapeutics's ROE % for the quarter that ended in Sep. 2019 was -2,103.94%. Melinta Therapeutics's PB Ratio for the quarter that ended in Sep. 2019 was N/A. Melinta Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2019 was N/A.

Melinta Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for Melinta Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Melinta Therapeutics ROE % Adjusted to Book Value Chart

Melinta Therapeutics Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-6.52

-7.57

-520.91

Melinta Therapeutics Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-47.83	-361.22	-241.25	-162.45	-

Competitive Comparison of Melinta Therapeutics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Melinta Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Melinta Therapeutics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Melinta Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Melinta Therapeutics's ROE % Adjusted to Book Value falls into.

Melinta Therapeutics ROE % Adjusted to Book Value Calculation

Melinta Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2018 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-119.81%	/	0.23
	=	-520.91%

Melinta Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2019 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-2,103.94%	/	N/A
	=	N/A

Melinta Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Melinta Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Melinta Therapeutics (Melinta Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Melinta Therapeutics Inc (OTCPK:MLNTQ) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

44 Whippany Road, Morristown, NJ, USA, 07963

Website

http://www.melinta.com

Melinta Therapeutics Inc is a clinical-stage biotechnology company that develops differentiated antibiotics for acute care and community settings. The company's goal is to develop treatments for bacterial infectious diseases, particularly respiratory tract infections and staphylococcal infections. The company is particularly focused on treating community-acquired bacterial pneumonia, as well as gonorrhea and other indications.

Executives

John Johnson	director, officer: Chief Executive Officer	DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101
Thomas P Koestler	director	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
David Zaccardelli	director	300 TRI STATE INTERNATIONAL, SUITE 272, LINCOLNSHIRE IL 60069
David N Gill	director	C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843
Bruce Downey	director
Garheng Kong	director	712 COLLEGE AVENUE, MENLO PARK CA 94025
Daniel Mark Wechsler	director, officer: See Remarks	2150 ST. ELZEAR BLVD. WEST, LAVAL A8 H7L 4A8
John Temperato	officer: Chief Commercial Officer	C/O MELINTA THERAPEUTICS,INC., 300 GEORGE STREET, SUITE 301, NEW HAVEN CT 06511
Goldstein Dov A Md	director
Michael R Dougherty	director	C/O ADOLOR CORP, 700 PENNSYLVANIA DR, EXTON PA 19341
P Sherrill Neff	director	C/O RESOURCE AMERICA, INC., 1845 WALNUT STREET, 18TH FLOOR, PHILADELPHIA PA 19103
Prabhavathi Fernandes	director, officer: President and CEO	114 MILTON AVENUE, CHAPEL HILL NC 27514
Intersouth Partners Vii L P	10 percent owner	406 BLACKWELL SUITE 200, DURHAM NC 27701
Intersouth Associates Vii, Llc	10 percent owner	406 BLACKWELL STREET, SUITE 200, DURHAM NC 27701
Intersouth Associates Vi, Llc	10 percent owner	406 BLACKWELL STREET, SUITE 200, DURHAM NC 27701